

3 June 2019

NSX Announcement

Appointment of Directors

Beroni Group Limited (NSX:BTG) (“Beroni” or “the Company”) is pleased to announce Mr Warwick Dawson and Mr Tameyuki Kawaguchi have been appointed as the Non-Executive Directors of the Company, effective today.

Mr Dawson is currently a director of the Knowledge Exchange Team in the Division of Enterprise at the University of New South Wales. His roles encompass managing technology transfer and commercialisation, business development across all research and non-award education channels, Torch Innovation Precinct at UNSW and Unisearch (consulting and expert opinion). Mr Dawson is also leading the development of pipeline projects and funding for the University, with \$60m research contracts signed and a further \$100m under negotiation. Mr Dawson was previously a director of Research Office for the University of Sydney, managing all public and non-commercial research funding for all 16 faculties with funds under management of circa \$250m per annum.

Mr Tameyuki Kawaguchi is the current CEO of Medicine Plus Co., Ltd (Medicine Plus) which he founded in 2005. Medicine Plus sells a wide range of medical drugs, health foods, supplements, cosmetic products and household goods in the Japanese market. Mr Kawaguchi is the pioneer of Medicine Plus' new retail marketing model combining online with offline sales channels for Japanese pharmaceutical products. He has 40 years of business management experience. He has led Medicine Plus to develop nearly 80 own brand products, 7,500 offline sales channels and more than 800,000 online members. He now focuses on developing the global market for sales of Medicine Plus' “made in Japan” health products, in collaboration with Beroni.

-End-

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911

E: jacky.zhang@beronigroup.com

Mr Peter Wong
Executive Director and CFO
Tel: +61 423 727 580

E: peter.wong@beronigroup.com

About Beroni Group Limited (NSX:BTG) (OTCQX:BNIGF)

Beroni Group is an international biotechnological company listed on the National Stock Exchange of Australia and on the OTC markets in the U.S.A.. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.

Beroni Group's overall strategic goal is to become a world's leading enterprise in the biotechnology, life sciences and environmental science industries.